134 related articles for article (PubMed ID: 35029130)
1. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.
Tufail M; Wu C
Ther Deliv; 2022 Mar; 13(3):167-186. PubMed ID: 35029130
[TBL] [Abstract][Full Text] [Related]
2. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
Lin EH; Lenz HJ; Saleh MN; Mackenzie MJ; Knost JA; Pathiraja K; Langdon RB; Yao SL; Lu BD
Cancer Med; 2014 Aug; 3(4):988-97. PubMed ID: 24905030
[TBL] [Abstract][Full Text] [Related]
4. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Codony-Servat J; Cuatrecasas M; Asensio E; Montironi C; Martínez-Cardús A; Marín-Aguilera M; Horndler C; Martínez-Balibrea E; Rubini M; Jares P; Reig O; Victoria I; Gaba L; Martín-Richard M; Alonso V; Escudero P; Fernández-Martos C; Feliu J; Méndez JC; Méndez M; Gallego J; Salud A; Rojo F; Castells A; Prat A; Rosell R; García-Albéniz X; Camps J; Maurel J
Br J Cancer; 2017 Dec; 117(12):1777-1786. PubMed ID: 29123263
[TBL] [Abstract][Full Text] [Related]
5. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
6. Targeting the IGF-1R: The Tale of the Tortoise and the Hare.
Crudden C; Girnita A; Girnita L
Front Endocrinol (Lausanne); 2015; 6():64. PubMed ID: 25964779
[TBL] [Abstract][Full Text] [Related]
7. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
8. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
9. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
Int J Cancer; 2017 Jan; 140(2):431-439. PubMed ID: 27681944
[TBL] [Abstract][Full Text] [Related]
10. Production and characterization of monoclonal antibodies against insulin-like growth factor type 1 receptor.
Keyhanfar M; Forbes BE; Cosgrove LJ; Wallace JC; Booker GW
Hybridoma (Larchmt); 2006 Aug; 25(4):230-7. PubMed ID: 16934020
[TBL] [Abstract][Full Text] [Related]
11. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
[TBL] [Abstract][Full Text] [Related]
12. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
13. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
14. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
[TBL] [Abstract][Full Text] [Related]
16. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy.
Ma H; Zhang T; Shen H; Cao H; Du J
Br J Clin Pharmacol; 2014 Jun; 77(6):917-28. PubMed ID: 24033707
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
Hewish M; Chau I; Cunningham D
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
[TBL] [Abstract][Full Text] [Related]
18. Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy.
Qu X; Wu Z; Dong W; Zhang T; Wang L; Pang Z; Ma W; Du J
Oncotarget; 2017 Apr; 8(17):29501-29518. PubMed ID: 28427155
[TBL] [Abstract][Full Text] [Related]
19. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
20. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]